RECURRENT FALLOPIAN TUBE CARCINOMA
Clinical trials for RECURRENT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo battles Tough-to-Treat ovarian cancer
Disease control OngoingThis study is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to standard platinum-based chemotherapy. It aims to see if taking two oral drugs, cediranib and olaparib, together works better than taking either drug alone or…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 23:05 UTC
-
Doctors test 'Trojan Horse' stem cells carrying Cancer-Killing virus
Disease control OngoingThis early-phase trial is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Researchers are using a patient's own fat-derived stem cells to carry a specially engineered measles virus directly to the cancer…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 03, 2026 23:05 UTC
-
Scientists test new drug duo in fight against tough cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new oral drug (MLN0128) when combined with an existing cancer drug (bevacizumab). It is for adults with recurrent glioblastoma (a type of brain tumor) or other advanced solid tumors that have not responded to standar…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug combo trial offers hope for Tough-to-Treat ovarian cancer
Disease control OngoingThis study aims to find the best drug combination to control recurrent ovarian cancer that has stopped responding to standard platinum-based chemotherapy. It is testing a chemotherapy drug (pegylated liposomal doxorubicin) alone or combined with one or two immunotherapy drugs (at…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Pill vs. IV drip: major trial tests easier treatment for returning ovarian cancer
Disease control OngoingThis large, late-stage trial is testing whether taking pills (olaparib alone or with cediranib) works as well or better than standard intravenous chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned but still responds to platinum drugs. …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Can an Immune-Boosting drug help a cancer pill fight ovarian cancer better?
Disease control OngoingThis study is testing if a combination of two drugs works better than one alone to control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It compares a standard targeted drug (olaparib) against that same drug plus an immunotherapy drug (tremelimumab). The main g…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New triple-threat treatment tested for tough-to-treat gynecologic cancers
Disease control OngoingThis study is testing whether combining three existing cancer drugs works better than current options for women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned or stopped responding to platinum chemotherapy. The trial will enroll 38 participa…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Floor Backes, MD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo tested in battle against Tough-to-Treat gynecologic cancers
Disease control OngoingThis early-stage study is testing a combination of two drugs, niraparib (a pill) and copanlisib (an IV infusion), for women whose ovarian, endometrial, or related cancers have returned after prior treatment. The main goals are to find the safest dose of this combination and to le…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New combo therapy aims to halt ovarian Cancer's return
Disease control OngoingThis study is testing if a two-drug combination can stop ovarian, fallopian tube, or primary peritoneal cancer from getting worse after it has come back. The treatment pairs an immunotherapy drug (pembrolizumab) that helps the immune system fight cancer with a chemotherapy drug (…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug duo aims to outsmart tough cancers
Disease control OngoingThis study tested a two-drug combination (veliparib and topotecan) for people with advanced solid tumors or ovarian cancer that has come back after initial treatment. The first phase aimed to find the safest and most effective dose. The second phase focused on seeing if the combi…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Major trial tests new combo to fight back when ovarian cancer returns
Disease control OngoingThis large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for recurrent ovarian cancer? early trial tests drug to boost chemo
Disease control OngoingThis early-stage study is testing whether adding an experimental drug called berzosertib (M6620) to standard chemotherapy (carboplatin and gemcitabine) is safe and might work better for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned. The main goal …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New hope for Tough-to-Treat ovarian cancers in early trial
Disease control OngoingThis early-stage study is testing a new two-drug combination for women with ovarian cancer that has returned after previous treatment. The main goal is to find the safest and most effective dose of an experimental pill (peposertib) when given with a standard chemotherapy drug. Re…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Hot chemo bath during surgery tested for Tough-to-Treat cancers
Disease control OngoingThis early-stage study is testing whether washing the abdomen with heated chemotherapy during cancer-removal surgery is safe and feasible for patients with advanced or recurrent ovarian, fallopian tube, uterine, or peritoneal cancers. The goal is to see if this approach, sometime…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Major cancer trial tests new drug combo for Tough-to-Treat ovarian cancer
Disease control OngoingThis large, late-stage trial is testing which combination of chemotherapy drugs works best for women with a specific type of ovarian or fallopian tube cancer (mucinous adenocarcinoma). It compares two standard drug pairs, with or without an added drug (bevacizumab) that blocks tu…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists test new pill cocktails in fight against tough cancers
Disease control OngoingThis early-stage trial is testing the safety and best doses of two different combinations of oral medications for people with recurrent endometrial, ovarian, or triple-negative breast cancer. The study combines an existing drug (olaparib) with one of two newer drugs (AZD2014 or A…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for Tough-to-Treat ovarian cancers?
Disease control OngoingThis study is testing if adding an experimental drug called AZD1775 to a standard chemotherapy (gemcitabine) works better than the chemotherapy alone. It is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New hope for ovarian cancer patients when standard drugs fail
Disease control OngoingThis study is testing whether two different drug combinations can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer that has continued to grow despite previous treatment with a specific type of targeted therapy called a PARP inhibitor. It will enroll ab…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New hope for Tough-to-Treat ovarian cancer?
Disease control OngoingThis study is testing if adding a new drug called M6620 to a standard chemotherapy (gemcitabine) works better than the chemotherapy alone for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum drugs. The main goal is…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 04, 2026 15:30 UTC